Ovarian cancer screening using serum CA125 and transvaginal ultrasound: A systematic review and meta-analysis
In brief
Ovarian cancer screening detects 35% more Stage I cases but does not cut deaths
Across four randomized trials involving more than 375,000 women, screening with blood tests and transvaginal ultrasound did not significantly reduce ovarian cancer incidence or deaths from the disease. It detected 35% more Stage I cancers, but finding more early-stage cases did not translate into better overall outcomes, so the value of screening remains uncertain.
- Journal
- Gynecologic and obstetric investigation (Q2)
- Published
- 19 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Yu Chen, Yixuan Wu, Xintong Shi, Xiaoming Zhang, Qianyu Dai, Lihu Gu, et al.
- PMID
- 43056475
- DOI
- 10.1159/goi/aczag027
Why clinicians should know about it
- Picked for Epidemiology (top studies of the week, 22 November 2026): Population screening effectiveness and mortality; directly addresses screening harms
Abstract
BACKGROUND: The clinical utility of ovarian cancer screening remains unclear. This study aims to evaluate the effectiveness of serum cancer antigen 125 combined with transvaginal ultrasound in the early detection of ovarian cancer and the improvement of prognosis. METHODS: Systematically searched five electronic databases to identify eligible randomised controlled trials. The primary outcomes were ovarian cancer incidence and ovarian cancer-specific mortality. Results were evaluated using relative risks and 95% confidence intervals. RESULTS: Four randomised controlled trials were included in this meta-analysis, comprising 188147 participants in the screening group and 187394 in the control group. Pooled results showed no statistically significant difference in overall ovarian cancer incidence and ovarian cancer-specific mortality between the two groups (all p>0.05). Subgroup analysis further showed that the screening group had a significantly higher detection rate of Stage I ovarian cancer than the control group (relative risks=1.35, 95% confidence interval:1.14-1.60; p<0.001). For histological subtypes, the screening group had a significantly higher detection rate of serous carcinoma (relative risk=1.09, 95% confidence interval:1.01-1.19; p=0.030), but a significantly lower detection rate of mucinous carcinoma (relative risk=0.69, 95% confidence interval:0.51-0.94; p=0.020). No statistically significant difference was observed between the two groups in other subgroups (all p>0.05). CONCLUSION: For asymptomatic women in the general population, combined serum cancer antigen 125 and transvaginal ultrasound screening should be approached with caution. Current evidence indicates that this screening strategy neither reduced the overall incidence of ovarian cancer nor improved overall survival, despite potentially increasing the detection rate of Stage I and early-stage serous carcinoma.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.